Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is ...

Launch of Travoprost ophthalmic solution USP, 0.004 per cent adds to the company's portfolio of prescription ophthalmic products, said Glenmark Pharmaceuticals Senior Vice President, Jim Brown. Image ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of travoprost ophthalmic solution USP, 0.004% (ionic buffered solution). Glenmark’s travoprost ophthalmic solution USP, 0.004% is ...

Glenmark Pharmaceuticals on Wednesday, November 27, announced the launch of the Travoprost Ophthalmic Solution USP, 0.004%, by its subsidiary Glenmark Pharmaceuticals Inc., USA. The Travoprost ...

Travatan Z ophthalmic solution USP, 0.004 per cent of Sandoz, Inc, the company said in a statement. Glenmark Pharmaceuticals Inc Senior Vice President, Sales & Marketing Jim Brown said the launch of ...

Glenmark Pharmaceuticals has announced that its U.S. based subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Travoprost Ophthalmic Solution USP (Ionic Buffered Solution) in the U.S. market.